Chronic exposure to nicotine has been reported to increase the number of nicotinic acetylcholine receptors (AChRs) in brain. The mechanism of up-regulation for the ␣4␤2 AChR subtype, which accounts for the majority of high affinity nicotine binding in mammalian brain, has previously been shown to involve a decrease in the rate of ␣4␤2 AChR turnover. Here, we report an investigation of the extent and mechanism of nicotine-induced up-regulation of ␣3 AChRs and ␣7 AChR subtypes expressed in the human neuroblastoma cell line SH-SY5Y. Up-regulation of human ␣3 AChRs and ␣7 AChRs, unlike ␣4␤2 AChRs, requires much higher nicotine concentrations than are encountered in smokers; the extent of increase of surface AChRs is much less; and the mechanisms of up-regulation are different than with ␣4␤2 AChRs. The mechanisms of up-regulation may be different for ␣3 AChRs or ␣7 AChRs. Chronic treatment with nicotine or carbamylcholine, but not d-tubocurarine, mecamylamine, or dihydro-␤-erythroidine, induced a 500 -600% increase in the number of ␣3 AChRs but only a 30% increase in ␣7 AChRs. Chronic nicotine treatment did not increase affinity for nicotine or increase the amount of RNA for ␣3 or ␣7 subunits. The effect of nicotine on up-regulation of ␣7 AChRs was partially blocked by either d-tubocurarine or mecamylamine. The effect of nicotine treatment on the number of ␣3 AChRs was only slightly blocked by the antagonists d-tubocurarine, mecamylamine, or dihydro-␤-erythroidine at concentrations that efficiently block ␣3 AChR function. Most of the nicotineinduced increase in ␣3 AChRs was found to be intracellular. The ␣3 AChRs, which accumulate intracellularly, were shown to have been previously exposed on the cell surface by their susceptibility to antigenic modulation. The data suggest that chronic exposure to nicotine may induce a conformation of cell surface ␣3 AChRs that at least in this cell line are consequently internalized but not immediately destroyed.
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It is well established that chronic nicotine exposure results in increased binding of [ 3 H]nicotine and 125 I-␣Bgt in brain (1) (2) (3) (4) (5) (6) (7) (8) . AChRs composed of ␣4 and ␤2 subunits have high affinity for nicotine and ACh and account for most of the high affinity nicotine binding in rat brain (9 -11) . AChRs composed of ␣3 subunits in combination with ␤2, ␤4, and/or ␣5 subunits have lower affinity for ACh and nicotine than do ␣4␤2 AChRs and account for a small amount of high affinity nicotine binding in brain (12) . Flores et al. (4) showed that ␣4␤2 AChRs are increased in the cortex of rats chronically treated with nicotine. In addition, Collins et al. (5, 6) reported that chronic exposure to nicotine or the antagonist mecamylamine increased mouse brain [ 3 H]nicotine binding in numerous regions to various extents without increasing the levels of ␣4 or ␤2 AChR subunit mRNAs. We found that chronic treatment of Xenopus laevis oocytes expressing ␣4␤2 AChRs or a mouse fibroblast cell line permanently transfected with chicken ␣4␤2 AChRs with nicotine or mecamylamine caused a ϳ2-fold increase in ␣4␤2 AChRs (13) . The nicotine concentration dependence, time course, and extent of ␣4␤2 AChR up-regulation are similar to those reported for ␣4␤2 AChRs in mammalian brains. The nicotine-induced increase in ␣4␤2 AChRs is due to a decrease in the rate of ␣4␤2 AChR turnover (13) . This induction mechanism does not seem to require cation flow through ␣4␤2 AChRs because the channel blocker mecamylamine causes up-regulation (6, 13) . Nicotine and mecamylamine are synergistic in causing up-regulation (6, 13) because mecamylamine preferentially blocks open channels and nicotine is an agonist, so together they are more effective at accumulating the inactive conformation of ␣4␤2 AChR, which is turned over more slowly (13) . Neuronal AChRs that bind ␣Bgt have been found to contain ␣7, ␣8, or ␣9 subunits (14 -16) . ␣7 AChRs are the predominant form of ␣Bgt binding protein in brain (14) ; they have higher affinity for nicotine than for ACh but much lower affinity for nicotine than do ␣4␤2 AChRs (17). Marks et al. (7) reported that chronic intravenous infusion of mice with nicotine elicited an increase in brain 125 I-␣Bgt binding. The extent and duration of nicotine-induced up-regulation of 125 I-␣Bgt binding in rat brains were less than the increase in [ 3 H]nicotine binding (7) . More recently, Barrantes et al. (18) reported that chronic nicotine treatment of hippocampal neurons with nicotine elicits a 40% increase in the number of 125 I-␣Bgt binding sites. These results indicate that the up-regulation of ␣7-containing AChRs requires a higher dose of nicotine and a longer exposure time than does up-regulation of ␣4␤2 AChRs.
After we and others (13, 19, 20) determined that chronic exposure to nicotine causes up-regulation of the ␣4␤2 AChR subtype by reducing turnover, it seemed important to determine whether other AChR subtypes were similarly regulated. Differences in the effects of chronic nicotine exposure on various AChR subtypes might help to account for variations in the extent of nicotine-induced up-regulation of [ 3 H]nicotine binding in various brain regions (5) and for complexities in functional effects of chronic exposure to nicotine in smokers or chronic exposure to other nicotinic agonists that might be used for therapeutic purposes. The human neuroblastoma cell line SH-SY5Y, like chick ciliary ganglion neurons (21), expresses both ␣3 AChRs and ␣7 AChRs (22, 23) . These cells resemble human fetal sympathetic neurons grown in primary culture and express mRNAs for ␣3, ␣5, ␣7, ␤2, and ␤4 subunits (24) . They express ␣3-containing AChRs of at least two subtypes, half of which contain ␤2 subunits (23) , and which contain some mixture of ␣3␤2, ␣3␤2␣5, ␣3␤4, ␣3␤4␣5, and ␣3␤2␤4␣5 subtypes. They also express ␣7 AChRs that are either homomers of ␣7 subunits or contain ␣7 assembled with other, unidentified subunits (22, 24, 25) . Experiments were undertaken to investigate whether chronic exposure to nicotine of these cells induces up-regulation of ␣3 AChRs and ␣7 AChRs and the mechanisms that may be involved in this up-regulation.
Materials and Methods
Cell cultures. SH-SY5Y cells were initially provided by June Biedler and Barbara Spengler of the Sloan Kettering Institute for Cancer Research (26) . Cultures were grown in a 1:1 mixture of Ham's F12 medium and Eagle's minimal essential medium containing 1 ϫ 10 Ϫ4 M nonessential amino acids, supplemented with 10% fetal bovine serum, in a 95% air/5% CO 2 humidified incubator at 37°. pH of the L-nicotine (Sigma) solutions was adjusted with 10 N NaOH before being added to media. The cell monolayers were washed with PBS saline, scraped, pelleted in a microfuge at 4°, and stored at Ϫ80°u ntil use. mAbs. mAb210 was initially raised to the main immunogenic region on the extracellular surface of mammalian muscle ␣1 subunits (27) and was shown to cross-react with human ␣3 and ␣5 subunits (23) . mAb306 was prepared using as antigen a mixture of affinity-purified native and denatured ␣Bgt-binding AChRs from the brains of chickens and rats (14) and was found to cross-react with human ␣7 subunits in the SH-SY5Y cell line (22) .
Labeling reagents. P-dATPlabeled, human ␣3 or ␣7 subunit cDNA fragment or 32 P-UTP-labeled human ␤-actin RNA fragment in 40% formamide, 5ϫ Denhardt's solution (1ϫ Denhardt's solution contains 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 0.5% SDS, 5ϫ SSPE, and 0.15 mg/ml denatured salmon sperm DNA and incubated overnight at 42°for cDNA probes and at 60°for RNA probes. Human ␤-actin was used as a heterologous probe to determine the amount of human ␤-actin RNA expressed in the SH-SY5Y cell line by allowing for normalization of ␣3 and ␣7 mRNA signals within each lane. Membranes were washed at 50°in 1ϫ SSPE/0.1% SDS and exposed to Kodak XAR-5 film at Ϫ70°. Scanned images were quantified using NIH Image 1.54 software.
Cell surface binding. Confluent cells in 60-mm dishes were treated with or without 1 ϫ 10 Ϫ3 M nicotine for 4 days. To label ␣3 AChRs, cells were incubated with 1 ml of medium containing 1 ϫ 10 Ϫ8 M 125 I-mAb210 for overnight at 4°. Nonspecific binding was determined in the presence of 1 ϫ 10 Ϫ6 M unlabeled mAb210. ␣7 AChRs were similarly labeled using 1 ϫ 10 Ϫ8 M 125 I-␣Bgt overnight at 4°. Nonspecific binding was determined in the presence of 1 ϫ 10 Ϫ6 M unlabeled ␣Bgt. In both cases, cells were washed three times with 1 ml of PBS, detached, pelleted, and resuspended before ␥-counting.
Membrane fraction binding assays. Cells were grown just as for cell surface binding experiments and then harvested in PBS. Cells were lysed by incubation for 1 hr in 4°hypotonic buffer (5 mM Tris⅐HCl, pH 7.5) followed by homogenization (34) . Centrifugation at 40,000 ϫ g for 20 min yielded a crude membrane pellet, which was resuspended in PBS. Labeling with 1 ϫ 10 Ϫ8 M 125 I mAb210 or 125 I-␣Bgt was conducted overnight at 4°with gentle shaking. Unbound labels were removed by pelleting followed by three washes in PBS and repelleting before resuspension and ␥-counting. Nonspecific binding was determined in the presence of 1 ϫ 10 Ϫ6 M unlabeled ligand.
Immunoisolated AChR binding assays. For the [ 3 H]nicotine binding assay, ␣3 AChRs from SH-SY5Y were solubilized in 5 volumes of lysis buffer (containing 2% Triton X-100, 50 mM NaCl, 50 mM sodium phosphate buffer, pH 7.5, 5 mM EDTA, 5 mM EGTA, 2 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine, and 5 mM iodoacetamide) through brief vortexing followed by 20 min of gentle rotation at 4°and then a 20-min centrifugation in a microfuge at 4°. The ␣3 AChRs were immunoisolated by incubating overnight at 4°the solubilized AChR with mAb210-coated Immulon 4 microwells (Dynatech Labs, Chantilly, VA). The microwells were then washed three times, and 100 l of 2 ϫ 10 Ϫ8 M [ 3 H]nicotine in 0.5% Triton X-100 PBS buffer was added and incubated 1 hr at 4°. After three rapid washes, bound [ 3 H]nicotine was removed using sample buffer (2.5% SDS, 5% ␤-mercaptoethanol) and measured using a scintillation counter. For the 125 I-␣Bgt binding assay, solubilized AChRs were incubated with mAb306-coated Immulon 4 microwells overnight at 4°. The microwells were then rinsed and incubated with 100 l of 5 ϫ 10 -9 M 125 I-␣Bgt in 0.5% Triton X-100 PBS buffer, pH 7.5. After three washes, bound 125 I-␣Bgt was measured using a ␥-counter. Nonspecific binding was measured using wells lacking mAb.
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Electrophysiology. Electrophysiological recordings from X. laevis oocytes injected with 5 ng each of cRNAs for human AChR subunits in the combinations ␣3␤2, ␣3␤4, or ␣3␤2␤4␣5 were made as previously described (12, 23) . Data were collected 3 days after injection using oocytes voltage-clamped at Ϫ50 mV.
Antigenic modulation. Three 60-mm dishes of confluent SH-SY5Y cells for each condition were grown for 3 days with or without 1 ϫ 10 Ϫ3 M nicotine and/or 1 ϫ 10 Ϫ7 M mAb210. Cells from each dish were harvested separately and then lysed by incubation for 1 hr in 5 mM Tris⅐HCl buffer, pH 7.5, followed by homogenization for 10 sec using a Polytron. Membrane fragments were pelleted by centrifugation for 20 min at 40,000 ϫ g and then resuspended in 200 l of PBS. After incubation with 1 ϫ 10 Ϫ8 M [ 3 H]epibatidine for 2 hr at 4°with gentle agitation, the membranes were washed three times by filtration on Whatman GF/C filters with 3 ml of PBS. Nonspecific binding was determined in the presence of a 100-fold excess of unlabeled epibatidine. Bound [ Statistical analysis. Two-tailed t tests were used.
Results
Chronic exposure to nicotine of cultured SH-SY5Y cells caused a 575% increase in the amount of immunoisolated ␣3 AChRs but only a 30% increase in the amount of immunoisolated ␣7 AChRs (Fig. 1) . mAb210, which binds to both ␣3 and ␣5 subunits (23), and mAb306, which binds to ␣7 subunits (22) , were used to tether AChRs that had been solubilized with Triton X-100. Measurement of total ␣3 AChRs by binding 125 I mAb210 or total ␣7 AChRs by binding 125 I-␣Bgt to cell membrane fragments gave results similar to those obtained using immunoisolated solubilized AChR subtypes (data not shown). The half-maximally effective concentrations of nicotine for up-regulation (EC 50 ), assuming that 1 ϫ 10 Ϫ3 M nicotine gave the maximum response, were 1 ϫ 10
Ϫ4
M for ␣3 AChRs and 6.5 ϫ 10 Ϫ5 M for ␣7 AChRs. This contrasts with the much lower EC 50 value for up-regulation of ␣4␤2 AChRs of 2 ϫ 10 Ϫ7 M that we had previously observed (13) . At a concentration of 1 ϫ 10 Ϫ3 M, nicotine did not affect cell proliferation. At 10 Ϫ2 M nicotine, cells started to detach from the dishes, so 1 ϫ 10 Ϫ3 M was the highest concentration used. Unlike the case with ␣4␤2 AChRs (13), mecamylamine at a concentration of 1 ϫ 10 Ϫ3 M did not cause up-regulation of either ␣3 or ␣7 AChRs.
Kinetics of up-regulation of ␣3 AChRs differed from those of ␣7 AChRs (Fig. 2) . The increase of ␣3 AChRs was seen as early as 5 hr after nicotine exposure, and the maximum effect was seen after 3 days. Up-regulation of ␣7 AChRs was seen after an 8-hr exposure and was complete within 24 hr.
The up-regulation resulted from an increase in the amount of AChR rather than from an increase in the affinity of ␣3 AChRs for nicotine. This was shown by Scatchard plots of [ 3 H]nicotine binding to control and chronically nicotinetreated SH-SY5Y cells (Fig. 3) . There are two populations of ␣3 AChRs in the SH-SY5Y cell line that differ in affinity for nicotine. The affinity of each population for nicotine was not significantly changed after up-regulation.
Northern analysis was used to determine whether the increased AChRs were due to an increased RNA level. Poly(A) ϩ -tailed mRNA was isolated from cells treated with or without 1 ϫ 10 Ϫ3 M nicotine for 4 days. Nicotine treatment did not up-regulate the steady state amounts of mRNA for ␣3 or ␣7 subunits in SH-SY5Y cells (Fig. 4) . The average values from two independent experiments revealed ratios of nicotine-treated to control values of 1.0 for ␣3 mRNA and 0.84 for ␣7 mRNA. These results indicated that nicotine up-regulates both ␣3 and ␣7 AChRs via post-transcriptional mechanisms.
Most of the ␣3 AChRs induced by nicotine were found in an intracellular compartment (Fig. 5 ). To test whether this might be due to nicotine acting inside the cells to facilitate ␣3 AChR synthesis or assembly, up-regulation by carbamylcholine was also tested. Although nicotine is a tertiary amine that can cross cell membranes, carbamylcholine is a quaternary amine that cannot penetrate the cells to act on ␣3 AChR synthesis. Carbamylcholine also caused an increase in intracellular ␣3 AChRs (Fig. 5) ; this suggests that either carbamylcholine mediated an increase in internal ␣3 AChRs through mechanisms subsequent to cation flow through ␣3 AChRs that it stimulated on the surface or that the internal ␣3 AChRs had been on the surface to interact with carbamylcholine at some time during the 4-day incubation. Surface ␣3 AChRs were quantified by binding of 125 I-mAb210 to intact cells, and total ␣3 AChRs were quantified by binding to membrane fragments. Measurements of total ␣3 AChRs by binding of [ 3 H]nicotine to detergent-solubilized ␣3 AChRs immunoisolated on mAb210-coated microwells gave similar results (data not shown). Chronic treatment with either nicotine or carbamylcholine caused a Ͼ 300% increase in the total amount of ␣3 AChRs in SY-SY5Y cells but only about a 30% increase in ␣3 AChRs on the cell surface.
Chronic treatment of SH-SY5Y cells with a high concen- to provide a 100-fold molar excess of antagonist, the upregulation of ␣3 AChRs was not significantly blocked (Fig. 6) . A 100-fold molar excess of the antagonists was very effective at blocking cation flow through ␣3 AChRs (Fig. 6 ). This suggests that up-regulation of ␣3 AChRs induced by agonists does not require cation flow through these AChRs. A 100-fold molar excess of the noncompetitive antagonist, as expected, did not inhibit [ 3 H]nicotine binding. The competitive antagonists at this concentration ratio inhibited [ 3 H]nicotine binding substantially but not completely (Fig. 6 ). This suggests that during the 4-day incubation with both nicotine and antagonists, a substantial fraction of the ACh binding sites were occupied by nicotine at any given moment (100% for mecamylamine, 24 -28% for curare and DH␤E). Antagonists bound to one or more of the ACh binding sites or to the cation channel would prevent cation flow through these ␣3 AChRs. However, nicotine bound to the remaining ACh binding sites might be able to produce some level of functional desensitization and perhaps other consequent effects, such as internalization and up-regulation.
Evidence that the internalized ␣3 AChRs induced by agonists had been on the cell surface at some point during the 4 days of incubation with agonist was provided by showing that nicotine-induced ␣3 AChRs on SH-SY5Y cells were susceptible to antigenic modulation by mAb210 (Fig. 7) . It is well known that both antibodies to the main immunogenic region on the extracellular surface of muscle AChR ␣1 subunits (e.g., mAb210) and autoantibodies to muscle AChRs that are from patients with myasthenia gravis cause down-regulation of AChRs via the process of antigenic modulation (35). This involves cross-linking of AChRs by antibodies, which facilitates their endocytosis and lysosomal destruction. Because mAbs cannot cross cell membranes, demonstration that mAb210 can prevent most of the nicotine-induced increase in ␣3 AChRs shows that those ␣3 AChRs must have been exposed on the surface membrane, where they were accessible to binding by the mAb. The observation that mAb210 did not significantly reduce the amount of ␣3 AChRs in cells that were not exposed to nicotine may result from the normally very low density of ␣3 AChRs in these cells, which may make it difficult to cross-link these AChRs into aggregates sufficiently large to speed endocytosis.
The rate of degradation of ␣3 AChRs in SH-SY5Y cells was assayed using the same approach that we had used to detect a nicotine-induced decrease in the rate of degradation in ␣4␤2 AChRs permanently transfected into mouse fibroblasts (13) (Fig. 8) . This method involves the use of cycloheximide to prevent the synthesis of new AChRs, followed by measurement of the rate of loss of existing AChRs in the presence or absence of nicotine. Unlike what we had observed with ␣4␤2 AChRs (13), the presence of nicotine did not slow the rate of loss of ␣3 AChRs (Fig. 8) . This was unexpected because it seemed reasonable to suppose that the nicotine-induced increase in internalized ␣3 AChRs that we had observed would be reflected in a decrease in turnover rate. However, it may be that prevention of lysosomal destruction of the internalized ␣3 AChRs that accumulate in the presence of nicotine depends on the continued synthesis of a protein, with the result that when protein synthesis is blocked with cycloheximide, not only the synthesis of new ␣3 AChRs but inhibition of the destruction of the internalized ␣3 AChRs is prevented.
The slight extent of up-regulation of ␣7 AChRs induced by nicotine was substantially blocked by both curare and mecamylamine (Fig. 9 ). The differences in extent and antagonist sensitivity of up-regulation of ␣7 AChRs compared with those of ␣3 AChRs suggest that different mechanisms may be involved in nicotine-induced up-regulation of these two AChR subtypes.
Discussion
We found that human ␣3 and ␣7 AChRs are up-regulated by chronic exposure to nicotine but only at concentrations of nicotine much higher than those required for up-regulation of ␣4␤2 AChRs (13) . The maximum extent of up-regulation was least for ␣7 AChRs, intermediate for ␣4␤2 AChRs, and highest for ␣3 AChRs. However, the large amounts of nicotineinduced ␣3 AChRs are found intracellularly, where they would not be functional; this is summarized in Table 1 . In normal rat brains, there seems to be approximately equal amounts of ␣7 and ␣4␤2 AChRs but much fewer ␣3 AChRs. ␣4␤2 AChRs are up-regulated with an EC 50 value of 2 ϫ 10 Ϫ7 M nicotine, which also is a serum concentration that is typical of tobacco users (29) , whereas up-regulation of ␣3 and ␣7 AChRs requires nicotine concentrations of Ն400-fold higher. Both ␣3 and ␣7 AChRs require much higher nicotine concentrations for activation than do ␣4␤2 AChRs, and the equilibrium binding affinity for nicotine of their presumably desensitized states is much lower than that of ␣4␤2 AChRs. There is no precise correlation between K D values for binding or EC 50 values for activation and EC 50 values for up-regulation Amounts of ␣3 and ␣7 subunit mRNAs were measured using a Northern blot. A series of exposures ensured that the measurements were made in the linear range. Each set of blots was successively used to quantify an AChR subunit, and then ␤-actin was used as an internal control. Quantification by scanning of the autoradiographs and normalization to the ␤-actin control revealed average ratios of nicotine treated to control values of 1.0 for ␣3 and 0.84 for ␣7 for the two experiments. of any of these AChR subtypes. In all cases, the EC 50 value for up-regulation is closer to the EC 50 value for activation than it is to the K D value for equilibrium binding. However, as we discussed previously regarding ␣4␤2 AChRs (13) and as shown in the current study for ␣3 AChRs (Fig. 6) , the inability of channel blockers to prevent nicotine-induced upregulation argues strongly that for those subtypes, AChR activation is not required for up-regulation. In the case of ␣7 AChRs, both curare and mecamylamine seemed to block the small amount of nicotine-induced up-regulation, so in the case of this subtype, up-regulation may depend on AChR activation.
Total ␣3 AChRs in SH-SY5Y cells could be up-regulated to a larger extent (575%) (Fig. 1) than the 100% that is typical of chick ␣4␤2 AChRs (13) or mammalian brain ␣4␤2 AChRs (4), but the extent of surface up-regulation of ␣3 AChRs was only 30 -40% (Fig. 5) . Thus, if the effects in SH-SY5Y cells reflect the effects of chronic nicotine exposure on human brain and ganglia, one might expect little nicotine-induced increase in the number of surface ␣3 AChRs or ␣7 AChRs in contrast with a doubling of surface ␣4␤2 AChRs. However, because nicotine can also induce functional desensitization of AChRs and the extent and reversibility of this desensitization may vary with AChR subtype, the net relative sensitivity of various AChR subtypes after chronic exposure to nicotine may not be reflected even in the relative amounts of various AChR subtypes in cell surfaces.
The agonist-induced increase in [ 3 H]nicotine binding to immunoisolated AChRs results from an increase in the amount of AChRs rather than from an increase in the affinity of the AChRs for nicotine (Fig. 3) . There are two classes of binding sites for [ 3 H]nicotine in SH-SY5Y cells (K D1 ϭ 0.5 nM, K D2 ϭ 17 nM) (Fig. 3) . These results are similar to the results reported by Lukas et al. (24) . These two binding affinities may reflect the relative amounts of ␣3 AChR subtypes present among the possible ␣3␤2, ␣3␤2␣5, ␣3␤4, ␣3␤4␣5, and ␣3␤2␤4␣5 subunit combinations (23) . For example, we also found that half of the ␣3 AChRs in SH-SY5Y cells contain ␤2 subunits and that this half of the AChRs is associated with much higher affinity for epibatidine (23) . The effect of nicotine-induced regulation of ␣3 AChRs in SH-SY5Y cells differs from that in chick ciliary ganglion neurons (21) . The ␣3 AChRs expressed in chick ciliary ganglion neurons are reduced 30% by chronic exposure of cultures to carbamylcholine; this might be accounted for by differences in neuronal ␣7 AChRs were also up-regulated by nicotine (Fig. 1 ) but only by very high concentrations of nicotine and to a lesser degree than were ␣4␤2 AChRs (13). Up-regulation of ␣7 AChRs reached its maximum within 24 hr (Fig. 2) , mimicking the up-regulation observed in vivo (7) . In mice, higher nicotine doses are required to elicit increases in brain 125 I␣Bgt sites than are necessary to increase [ 3 H]nicotine binding sites, and the amounts of 125 I-␣Bgt sites change more rapidly (7, 31) . The relatively small magnitude of up-regulation for ␣7 is reminiscent of the small changes in 125 I-␣Bgt binding observed after in vivo administration of nicotine (7, 30) . Brain 125 I-␣Bgt binding sites are up-regulated only by higher doses of nicotine (32, 33) . This also reflected the lower level of up-regulation that resulted from chronic nicotine exposure of ␣Bgt binding sites compared with [ 3 H]nicotine binding sites that was observed in rat brain by Marks et al. (7) . Up-regulation of muscle-type AChRs expressed by TE671 cells required 1 ϫ 10 Ϫ3 M nicotine for significant up-regulation to occur (34, 36) . Thus, the effective nicotine concentration reflects the sensitivity of the particular nicotinic AChR subtype to this agonist.
The failure of nicotine to up-regulate transcription of ␣3 and ␣7 subunit mRNA (Fig. 4) while up-regulating the amount of ␣3 and ␣7 AChRs in SH-SY5Y cells is consistent with similar results observed in brain with ␣4␤2 AChRs (5) and suggests that nicotine also up-regulates ␣3 and ␣7 AChRs via post-transcriptional mechanisms. This is also reminiscent of results with ␣4␤2 AChRs in transfected cells (13, 37) .
In the case of ␣4␤2 AChRs, the competitive antagonist curare blocks nicotine-induced up-regulation of cell surface ␣4␤2 AChRs, the channel blocker mecamylamine causes upregulation and is synergistic with nicotine in causing upregulation (13) . This was interpreted to mean that agonists and mecamylamine induced a conformation, probably a desensitized conformation, of the ␣4␤2 AChRs that is turned over more slowly and that up-regulation does not require cation flow through the AChR.
The mechanism of ␣3 AChR up-regulation, although similarly post-transcriptional and also apparently not requiring cation flow through the AChRs (Fig. 6) , is different from that of ␣4␤2 AChRs, especially in accumulating a large excess of internal ␣3 AChRs in response to chronic exposure to high concentrations of nicotine. Unlike the effect on ␣4␤2 AChRs (13), the channel blocker mecamylamine itself does not cause up-regulation of ␣3 AChRs, and it had no synergistic effect with nicotine in causing up-regulation (Fig. 6 ). This suggests that mecamylamine does not induce the conformation of ␣3 AChRs required for up-regulation, but neither does it seem to prevent nicotine from inducing this conformation. The observation that after 3 days in the presence of nicotine most of the ␣3 AChRs induced by agonists were intracellular (Fig. 5 ) was unexpected; it presented the conundrum of reconciling the observation that a membrane-impermeable agonist could cause accumulation of intracellular ␣3 AChRs (Fig. 5) with the observation that antagonists could not block up-regulation (Fig. 6 ), which indicated that ion flow through ␣3 AChRs could not be used to signal the inside of the cell to more rapidly synthesize ␣3 AChRs. Demonstration that the nicotine-induced increase in ␣3 AChRs could be prevented by antigenic modulation (Fig. 7) showed that all of the ␣3 AChRs affected by nicotine had been on the surface, where they could bind membrane-impermeable quaternary amine ligands. Fig. 10 depicts the mechanism of antigenic modulation. We hypothesize that chronic exposure to agonists causes ␣3 AChRs to assume a conformation, perhaps a desensitized conformation, that at least in SH-SY5Y cells results in being internalized into a compartment in which they linger for a while before being degraded in lysosomes as they would be normally. This is also depicted diagrammatically in Fig. 10 . There is precedent for the idea that agonists can induce internalization of receptors into a compartment in which they are not immediately destroyed, as in the case of ␤-adrenergic receptors (38) . Nicotine-induced up-regulation of ␣3 and ␣7 AChRs may differ not only quantitatively (with ␣3 AChRs showing more extensive up-regulation; Fig. 1 ) but also qualitatively in the mechanisms of up-regulation. Ion flow through ␣3 AChRs does not seem to be required for nicotine-induced up-regulation because the channel blocker mecamylamine does not block up-regulation (Fig. 6 ). In the case of ␣7 AChRs, ion flow through the AChR may be involved in nicotine-induced upregulation because with ␣7 AChRs, both curare and mecamylamine are effective at blocking nicotine-induced upregulation (Fig. 9) . The EC 50 value for nicotine-induced upregulation of ␣7 AChRs is also close to their EC 50 value for activation (Table 1) .
Although in smokers the effects of nicotine concentrations on the up-regulation of ␣4␤2 AChRs seem to be large and the effects on surface ␣3 and ␣7 AChRs seem to be small, the amount of AChR is not the only important parameter in determination of behavioral responses to nicotine. Nicotineinduced reversible desensitization and permanent functional inactivation are also important. ␣4␤2 AChRs are subject to desensitization and inactivation by low concentrations of nicotine (13, 39) , whereas ␣3␤2 AChRs are reported to be resistant to such inactivation (39) , and ␣7 AChRs are much more subject to rapid and extensive desensitization than are ␣4␤2 AChRs (40) . Thus, perhaps in chronic smokers, most ␣4␤2 AChRs are inactivated at average serum nicotine concentrations and some ␣3 AChR subtypes or other AChR subtypes are left by default to respond to the transient high bolus doses of nicotine in smokers.
The differential effects of nicotinic ligands on the activation, up-regulation, and desensitization of various subtypes of AChRs are likely to be important as new subtype-selective 
